TY - JOUR
T1 - Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
AU - Seldin, David C.
AU - Anderson, Jennifer J.
AU - Skinner, Martha
AU - Malek, Karim
AU - Wright, Daniel G.
AU - Quillen, Karen
AU - Finn, Kathleen
AU - Oran, Betul
AU - Sanchorawala, Vaishali
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Recently, protocols using high-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been developed for the treatment of patients with immunoglobulin light chain (AL) amyloidosis. Although peritransplantation mortality is greater than for other hematologic diseases, treatment leads to durable hematologic complete responses, improvements in organ function and quality of life, and extended survival in a substantial proportion of patients. To determine whether this treatment can be applied to older patients, we have analyzed HDM/SCT treatment outcomes for 65 patients (aged 65 years or older) with AL amyloidosis compared with outcomes for 280 younger patients. For patients over age 65 years who meet the same eligibility criteria as younger patients, toxicity, hematologic remission rate, and survival were not significantly different from those observed in younger patients, indicating that older patients should not be excluded a priori from consideration for HDM/SCT treatment.
AB - Recently, protocols using high-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been developed for the treatment of patients with immunoglobulin light chain (AL) amyloidosis. Although peritransplantation mortality is greater than for other hematologic diseases, treatment leads to durable hematologic complete responses, improvements in organ function and quality of life, and extended survival in a substantial proportion of patients. To determine whether this treatment can be applied to older patients, we have analyzed HDM/SCT treatment outcomes for 65 patients (aged 65 years or older) with AL amyloidosis compared with outcomes for 280 younger patients. For patients over age 65 years who meet the same eligibility criteria as younger patients, toxicity, hematologic remission rate, and survival were not significantly different from those observed in younger patients, indicating that older patients should not be excluded a priori from consideration for HDM/SCT treatment.
UR - http://www.scopus.com/inward/record.url?scp=33845267235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845267235&partnerID=8YFLogxK
U2 - 10.1182/blood-2006-06-029728
DO - 10.1182/blood-2006-06-029728
M3 - Article
C2 - 16926284
AN - SCOPUS:33845267235
SN - 0006-4971
VL - 108
SP - 3945
EP - 3947
JO - Blood
JF - Blood
IS - 12
ER -